BUZZ-Acelyrin tumbles on concerns over new dosing regimen in eye drug trial

Shares of drug developer Acelyrin SLRN.O tumble ~42% to $2.03

On Monday, SLRN said it was moving to a new dosing regimen with its thyroid eye disease drug, lonigutamab, after it showed comparable efficacy in a mid-stage trial

Co said in mid-stage trial it used a 50 mg initial dose followed by 25 mg weekly, while in a late-stage trial it plans to use a 100 mg initial dose followed by 50 mg every two weeks

H.C. Wainwright analyst Emily Bodnar told Reuters co has not evaluated the late-stage trial dosing regimen in TED patients, which creates risk as the safety and efficacy have not been established with this regimen for those patients

During the trial co's drug demonstrated efficacy comparable to the current IV-administered standard of care for treating thyroid eye disease (TED)

TED is a rare condition where the tissues behind the eye get inflamed causing the eyes to bulge and swell, leading to vision problems

Co said it plans to initiate late-stage trial in Q1 2025

SLRN declined ~58% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))